BML-286
- Product Name
- BML-286
- CAS No.
- 294891-81-9
- Chemical Name
- BML-286
- Synonyms
- BML-286;2-[[3-[(phenylacetyl)aMino]benzoyl]aMino]benzoic Acid;2-[[3-[(2-phenylacetyl)aMino]benzoyl]aMino]benzoic Acid;Benzoic acid, 2-[[3-[(2-phenylacetyl)amino]benzoyl]amino]-;Dvl-PDZ Domain Inhibitor II - CAS 294891-81-9 - Calbiochem
- CBNumber
- CB32557989
- Molecular Formula
- C22H18N2O4
- Formula Weight
- 374.39
- MOL File
- 294891-81-9.mol
BML-286 Property
- storage temp.
- +2C to +8C
- form
- White solid
N-Bromosuccinimide Price
- Product number
- 322338
- Product name
- Dvl-PDZ Domain Inhibitor II - CAS 294891-81-9 - Calbiochem
- Packaging
- 10mg
- Price
- $144
- Updated
- 2024/03/01
- Product number
- B595870
- Product name
- BML-286
- Packaging
- 50mg
- Price
- $165
- Updated
- 2021/12/16
- Product number
- 004331
- Product name
- BML-286
- Packaging
- 50mg
- Price
- $460
- Updated
- 2021/12/16
BML-286 Chemical Properties,Usage,Production
Uses
BML-286 is a small molecule inhibitor of the PDZ domain of Dishevelled (Dvl): an essential protein in the Wnt signaling pathways. This compound reduced the levels of apoptosis in the hyaloid vessels of the eye and also suppressed the growth of prostate cancer PC-3 cells. It is a useful tool for studies dissecting the Wnt signaling pathways.
Definition
ChEBI: 2-[[oxo-[3-[(1-oxo-2-phenylethyl)amino]phenyl]methyl]amino]benzoic acid is a member of benzamides.
General Description
A cell-permeable amidobenzanilide compound that disrupts Fz-Dvl (frizzled-dishevelled) interaction by targeting the PDZ domain (Kd = 10.6 μM) of Dvl, blocking Wnt3a-induced (10 ng/ml) transcription activity (~50% inhibition at 3 μM in 293 cell SuperTopflash reporter assays) and suppressing the Wnt pathway-dependent growth of prostate cancer PC-3 cells (by 16% in 72 h at ≥50 μM; IC50 = 12.5 μM). Shown to effectively prevent Wnt3A mRNA injection-induced xenopus embryo deformation (effective conc. = 25 μM) and suppress Wnt pathway-mediated apoptosis of the hyaloid vescular endothelial cells in the mouse eyes via vitreous injection (144 fmol/120 nl/eye) in vivo.